10x Genomics (TXG) Operating Expenses (2018 - 2026)

10x Genomics has disclosed Operating Expenses across 9 years of filings, most recently posting $123.2 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $123.2 million, down 14.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $483.3 million (down 19.37% YoY), and the FY2025 annual result was $504.9 million, down 17.1% from the prior year.
• Operating Expenses came in at $123.2 million for Q1 2026 at 10x Genomics, down from $132.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $190.3 million in Q3 2023 to a low of $95.0 million in Q2 2025.
• The 5-year median for Operating Expenses is $146.0 million (2024), against an average of $145.6 million.
• Across the five-year window, Operating Expenses jumped 35.28% in 2023 and slumped 34.94% in 2025, its largest moves.
• 10x Genomics' Operating Expenses stood at $142.5 million in 2022, then grew by 19.98% to $171.0 million in 2023, then decreased by 5.95% to $160.8 million in 2024, then retreated by 17.54% to $132.6 million in 2025, then retreated by 7.06% to $123.2 million in 2026.
• The last three Operating Expenses figures came in at $123.2 million (Q1 2026), $132.6 million (Q4 2025), and $132.5 million (Q3 2025), per Business Quant data.